Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Oramed Pharmaceuticals Inc announces FDA phase 2A clinical trial results


Thursday, 30 Jan 2014 04:00am EST 

Oramed Pharmaceuticals Inc:Announces the results from its Phase 2a clinical trial for its ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes.Says the trial was conducted under a United States Food and Drug Administration (FDA) IND (Investigational New Drug) protocol.Says the Phase 2a study met all primary and secondary endpoints. 

Company Quote